{"nctId":"NCT01850030","briefTitle":"A Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization","startDateStruct":{"date":"2013-08"},"conditions":["Female Infertility"],"count":1070,"armGroups":[{"label":"Dydrogesterone 30 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Dydrogesterone 30 mg","Drug: Placebo progesterone"]},{"label":"Micronized Progesterone 600 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Micronized Progesterone 600 mg","Drug: Placebo dydrogesterone"]}],"interventions":[{"name":"Dydrogesterone 30 mg","otherNames":[]},{"name":"Micronized Progesterone 600 mg","otherNames":[]},{"name":"Placebo progesterone","otherNames":[]},{"name":"Placebo dydrogesterone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent\n* Premenopausal females, age \\> 18 years \\< 42 years\n* Non-smokers. For females who were past smokers, they must have stopped tobacco usage for at least 3 months prior baseline visit\n* Early follicular phase (Day 2-4) Follicle stimulating hormone (FSH) less than or equal to 15 IU/L and estradiol (E2)within normal limits\n* Luteinizing hormone (LH), prolactin (PRL), T (testosterone) and thyroid-stimulating hormone (TSH), within the normal limits for the clinical laboratory, or considered not clinically significant by the Investigator within 6 months prior to screening\n* Documented history of infertility (e.g., unable to conceive for at least one year or for 6 months for women ≥ 38 years of age or bilateral tubal occlusion or absence)\n* Normal transvaginal ultrasound at screening (or within 14 days of screening) without evidence of clinically significant abnormality consistent with finding adequate for Assisted Reproductive Technology (ART) with respect to uterus and adnexa (no hydrosalpinx or clinically relevant uterine fibroids)\n* Negative pregnancy test on the day of pituitary down regulation (prior to administration of gonadotropin releasing hormones (GnRH) agonist or GnRH antagonist)\n* Clinically indicated protocol for induction of IVF with a fresh embryo\n* Single or dual embryo transfer\n* BMI ≥ 18 and ≤ 30 kg/m2\n\nExclusion Criteria:\n\n* Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematologic/immunologic, head, ears, eyes, nose, throat (HEENT), dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurologic/psychiatric, allergy, recent major surgery (\\< 3 months), or other relevant diseases as revealed by history, physical examination and/or laboratory assessments which could limit participation in or completion of the study\n* Acute urogenital disease\n* Known allergic reactions to progesterone products\n* Known allergic reactions to peanuts and peanut oil\n* Intake of experimental drug or participation in any other clinical trial within 30 days prior to study start\n* Mental disability or any other lack of fitness, in the Investigator's opinion, to preclude subjects to participate in or to complete the study\n* Current or recent substance abuse, including alcohol and tobacco (Note: Patients who stopped tobacco usage at least 3 months prior to screening visit would be allowed)\n* History of chemotherapy or radiotherapy\n* Patients with more than 3 unsuccessful IVF attempts\n* Contraindication for pregnancy\n* Refusal or inability to comply with the requirements of the study protocol for any reason, including scheduled clinic visits and laboratory tests\n* History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"19 Years","maximumAge":"41 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Being Pregnant as Measured by the Presence of Fetal Heart Beats at 12 Weeks´Gestation Using Transvaginal Ultrasound","description":"Percentage of participants being pregnant as measured by the presence of fetal heart beats at 12 weeks´gestation using transvaginal ultrasound","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":null},{"groupId":"OG001","value":"33.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Being Pregnant as Measured by the Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer","description":"Percentage of participants being pregnant as measured by the positive biochemical pregnancy test on Day 14 after embryo transfer","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","spread":null},{"groupId":"OG001","value":"45.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Successful Completion of Pregnancy","description":"Incidence of live births and healthy newborns","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6","spread":null},{"groupId":"OG001","value":"29.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"27.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Gender of the Newborn","description":"was recorded and collected for Newborn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":56,"n":518},"commonTop":["Vaginal haemorrhage","Procedural pain","Nausea","Headache","Abdominal pain"]}}}